LEXINGTON, Ky. (LEX 18) — Keeneland and Fasig-Tipton have announced changes in medication policies for horse sales.
The change restricts the use of non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids and bronchodilators, including Clenbuterol, for all horses sold at Keeneland and Fasig-Tipton. These new rules go into effect immediately.
These restrictions are in addition to other restrictions put in place for two-year-old sales held at Keeneland and Fasig-Tipton.
Keeneland President and CEO Bill Thomason and Fasig-Tipton President Boyd T. Browning Jr. said in a joint statement: “We remain united in our advocacy to serve the best interest of the horse. The use of medication is the most critical issue facing the Thoroughbred industry, and one that threatens the confidence of both the marketplace and the public. These reforms continue to promote transparency and integrity, and in doing so, strengthen the entire auction process.”
Officials say buyers may now elect to have post-sale testing for anabolic steroids, bisphosphonates, bronchodilators and the use of NSAIDs and corticosteroids in violation of the Conditions of Sale.
